The clocks are falling back early this year, but new study reveals Daylight Saving Time harms our health — here’s why Scientists reveal the true harm Daylight Saving Time has on our health and sleep Tom’s Guide · Sep 25, 2025
Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch On Wednesday, Eli Lilly Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began. Benzinga · Sep 25, 2025
Abandoning daylight saving time could prevent over 300,000 stroke cases a year in the US, study claims Springing forward by an hour each March knocks the circadian rhythm out of alignment. A new model of the chronic health impacts argues for scrapping it entirely. LiveScience · Sep 24, 2025
Roche Targets Top Spot In Weight Loss Drug Market Roche Holdings AG (OTC:RHHBY) on Monday outlined its plan to become a leading player in the surging weight-loss drug market, pushing its obesity pipeline farther into late-stage development as it eyes competition with Eli Lilly And Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO). Benzinga · Sep 22, 2025
Metsera Stock Rockets After Pfizer's $7.3b — Should You Still Invest? Metsera stock has soared after Pfizer announced a $7.3 billion acquisition, sparking investor buzz. Analysts are now weighing whether the biotech rally has more room to run or if buyers should stay cautious. International Business Times UK · Sep 22, 2025
Pfizer eyes obesity drug market as it seals $4.9bn deal for Metsera Pharma giant Pfizer is betting on obesity treatments as it looks for new markets following the success of its COVID-19 vaccine. Euronews · Sep 22, 2025
Pfizer Tries To Revitalize Obesity Portfolio With $5 Billion Matsera Deal Pfizer Inc. (NYSE:PFE) on Monday agreed to acquire Metsera, Inc. (NASDAQ:MTSR) to accelerate the next generation of medicines for obesity and cardiometabolic diseases. Benzinga · Sep 22, 2025
Pfizer amps up push into obesity treatments with $4.9B deal for Metsera Pfizer is doubling down on obesity treatments by spending $4.9 billion on the development-stage drugmaker Metsera The Independent UK · Sep 22, 2025
Pfizer Reportedly Nears Metsera Acquisition Deal: PFE Stock Climbs In Monday Pre-Market Pfizer Inc. (NYSE:PFE) stock climbed 1.54% in Monday pre-market amid reports that the company on the verge of acquiring Metsera Inc. (NASDAQ:MTSR), a developer of anti-obesity drugs. Benzinga · Sep 22, 2025
Could This New Drug Be The Safer Way To Fight Obesity? On Friday, Skye Bioscience, Inc. (NASDAQ:SKYE) announced the presentation of results from the Phase 1b study of nimacimab in subjects with metabolic-associated steatotic liver disease (MASLD) at the European Association for the Study of Diabetes (EASD) Annual Meeting. Benzinga · Sep 19, 2025
Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Eli Lilly stock rises on FDA fast-track hopes for its oral GLP-1 obesity drug and $27B U.S. manufacturing expansion; it's a tough trade but solid long-term hold MarketBeat · Sep 18, 2025
Novo Nordisk shares climb after positive anti-obesity pill results Danish drugmaker jumps by about £9bn as trial shows ‘significant weight loss’ with tablet version of Wegovy The Guardian - UK · Sep 18, 2025
New type of jab helps to maintain weight loss Experts have developed a new drug which helps tackle the underlying causes of obesity. The Independent UK · Sep 17, 2025
Vital breakthrough as once-a-day pill can help people lose ‘significant’ weight A fifth of people taking the weight-loss tablet Orforglipron lost 20 per cent of their body weight The Independent UK · Sep 16, 2025
The Independent UK · Sep 16, 2025 Abolishing daylight saving time could slash these life-threatening health conditions ‘We found that staying in standard time or staying in daylight saving time is definitely better than switching twice a year’
The Independent UK · Sep 16, 2025 FDA takes aim at Hims and other telehealth services in drug advertising blitz The Trump administration has issued its first warnings to online services that offer unofficial versions of popular drugs like the blockbuster obesity treatment Wegovy
Euronews · Sep 16, 2025 Doctors uncover genetic clues as to why obesity affects people differently A large-scale study compared body fat levels with markers of metabolic health, such as blood pressure, cholesterol and blood sugar.
Euronews · Sep 15, 2025 Weight loss drugs like Ozempic work well for kids and teens, study finds. But should kids take them? The popular drugs worked well to help children and adolescents lose weight and lower their blood sugar levels, a new review found.
The Independent UK · Sep 15, 2025 Obese children as young as six could benefit from weight-loss jabs About a third of children leaving primary school are overweight or living with obesity in England
Euronews · Sep 15, 2025 How are overweight and obesity affecting EU citizens? Overweight and obesity are rapidly increasing across Europe, a new study has found. In several Eastern European countries, three-quarters of men are overweight or obese.
The Guardian - US · Sep 14, 2025 Attack on obesity or cash grab? Tax hike on sugary drinks divides opinion in Mexico Mexicans, who consume on average 166 litres of fizzy drinks a year, will face a near doubling of the tax rate
Evening Standard · Sep 14, 2025 A life-changing journey powered by wheels of cheese There already exists a cure for ennui, and it’s found in the pub. But when former BBC producer and Canadian radio presenter Michael Finnerty — famous enough over there to have his face on billboards — finds his life without lustre, he does not turn to booze, which shows a…
The Guardian - UK · Sep 10, 2025 More than half of UK births now involve medical intervention, audit finds Caesareans drive rise in assisted deliveries as experts warn of complex pregnancies linked to age, obesity and other conditions
Radio France Internationale · Sep 10, 2025 More of the world's children are obese than underweight, UN warns For the first time, more school-aged children are obese than underweight around the world, with the exception of sub-Saharan Africa and South Asia. The warning came in a report released on Wednesday by the United Nations children’s agency Unicef.
Benzinga · Sep 10, 2025 Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative clinical effectiveness and value of Novo Nordisk A/S’ (NYSE:NVO) semaglutide (Wegovy) and Eli Lilly and Co.’s (NYSE:LLY) tirzepatide (Zepbound) for obesity management.